Covidien to repurchase $3B more in company shares

03/25/2013 | Clinica (subscription required)

A plan by Covidien to buy back $3 billion of its stock has been approved by the company's board, a move expected to benefit shareholders over the short term. In August 2011, the company also initiated a similar repurchase program, worth $2 billion.

View Full Article in:

Clinica (subscription required)

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
CareFusion
Minneapolis, MN
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
In house Compliance Officer
Confidential
Pompano Beach, FL